Overview
Efficacy of Pragmatic Same-day COVID-19 Ring Prophylaxis for Adult Individuals Exposed to SARS-CoV-2 in Switzerland
Status:
Completed
Completed
Trial end date:
2021-03-24
2021-03-24
Target enrollment:
0
0
Participant gender:
All
All
Summary
A study to assess, in a two-arm open-label cluster randomized clinical trial, the efficacy of a 5-day course of LPV/r treatment in preventing COVID-19 in asymptomatic individuals exposed to a SARS-CoV-2 documented index patient, compared to surveillance alone.Phase:
Phase 3Accepts Healthy Volunteers?
Accepts Healthy VolunteersDetails
Lead Sponsor:
Calmy AlexandraTreatments:
Hydroxychloroquine
Lopinavir
Ritonavir
Criteria
Inclusion criteria:1. Documented close contact with a person with either a PCR-confirmed SARS-CoV-2 or a
positive rapid SARS-CoV-2 antigen test (as per standard of care).
2. Enrolment of the participant no more than 7 days since last contact with index case;
3. ≥ 16 years of age;
4. Informed consent as documented by signature (including parent's or legal guardian's
signature if the participant is between 16 and 18 y.o.).
Exclusion criteria*:
1. Fever (temperature >38.0°C) and/or respiratory symptoms (cough, dyspnea) and/or new
anosmia/ageusia;
2. Individuals with previous confirmed SARS-CoV-2 infection, dating within the last six
months ;
3. Known impairment of liver function;
4. Known hypersensitivity to the study medications;
5. Use of any medications that are contraindicated with lopinavir/ritonavir using the
website www.hiv-druginteractions.org/checker
6. Individuals on boosted protease inhibitor (other than LPV) or boosted elvitegravir as
part of an antiretroviral therapy
7. Inability to be followed-up for the trial period
8. Documented vaccination against SARS-CoV-2
- Where necessary, additional biological and clinical assessment will be performed,
based on clinical judgement.